Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
General Thoracic and Cardiovascular Surgery
Published in: General Thoracic and Cardiovascular Surgery 9/2014

Open Access 01-09-2014 | Current Topics Review Article

Extrapleural pneumonectomy or pleurectomy/decortication for malignant pleural mesothelioma

Author: Seiki Hasegawa

Published in: General Thoracic and Cardiovascular Surgery | Issue 9/2014

Login to get access

Abstract

Malignant pleural mesothelioma (MPM) is associated with a very poor prognosis. Unlike other solid tumors, any type of planned surgery for MPM would be cytoreductive rather than radical. There are two types of surgery for MPM. Extrapleural pneumonectomy (EPP) involves en bloc resection of the lung, pleura, pericardium, and diaphragm. Pleurectomy/decortication (P/D) is a lung-sparing surgery that removes only parietal/visceral pleura. In comparison with EPP, P/D is theoretically less radical but is associated with less perioperative mortality/morbidity and less postoperative deterioration of cardiopulmonary function. It still remains unclear which surgical technique is superior in terms of the risk/benefit ratio. In this context, selection between EPP and P/D has been a matter to debate.
Literature
1.
Hasegawa S, Tanaka F. Malignant mesothelioma: current status and perspective in Japan and the world. Gen Thorac Cardiovasc Surg. 2008;56:317–23.PubMedCrossRef
2.
Murayama T, Takahashi K, Natori Y, Kurumatani N. Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model. Am J Ind Med. 2006;49:1–7.PubMedCrossRef
3.
4.
Le GV, Takahashi K, Park EK, et al. Asbestos use and asbestos-related diseases in Asia: past, present and future. Respirology. 2011;16:767–75.PubMedCrossRef
5.
6.
Amano J, Kuwano H, Yokomise H. Thoracic and cardiovascular surgery in Japan during 2011: annual report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2013;61:578–607.PubMedCrossRef
7.
Sugarbaker DJ. Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma. J Thorac Oncol. 2006;1:175–6.PubMedCrossRef
8.
Campbell NP, Kindler HL. Update on malignant pleural mesothelioma. Semin Respir Crit Care Med. 2011;32:102–10.PubMedCrossRef
9.
Flores RM. Surgical options in malignant pleural mesothelioma: extrapleural pneumonectomy or pleurectomy/decortication. Semin Thorac Cardiovasc Surg. 2009;21:149–53.PubMedCrossRef
10.
Rusch VW. Extrapleural pneumonectomy and extended pleurectomy/decortication for malignant pleural mesothelioma: the Memorial Sloan-Kettering Cancer Center approach. Ann Cardiothorac Surg. 2012;1:523–31.PubMedCentralPubMed
11.
Friedberg JS. The state of the art in the technical performance of lung-sparing operations for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2013;25:125–43.PubMedCrossRef
12.
Cameron RB. Extrapleural pneumonectomy is the preferred surgical management in the multimodality therapy of pleural mesothelioma: con argument. Ann Surg Oncol. 2007;14:1249–53.PubMedCrossRef
13.
Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011;12:763–72.PubMedCentralPubMedCrossRef
14.
15.
Weder W, Stahel R, Baas P, et al. The MARS feasibility trial: conclusions not supported by data. Lancet Oncol. 2011;12:1093–4.PubMedCrossRef
16.
Rusch VW, Giroux D, Kennedy C, et al. Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol. 2012;7:1631–9.PubMedCrossRef
17.
Rusch V, Baldini EH, Bueno R, et al. The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting Summary of the International Mesothelioma Interest Group Congress, September 11–14, 2012, Boston, Mass. J Thorac Cardiovasc Surg. 2013;145:909–10.PubMedCrossRef
18.
Treasure T, Utley M, O’Byrne K. MARS: a sense of perspective and an inconvenient truth. J Thorac Oncol. 2013;8:e48–9.PubMedCrossRef
19.
Rusch VW, Kindler HL. MARS: a sense of perspective and an inconvenient truth. J Thorac Oncol. 2013;8:e49–50.PubMedCrossRef
20.
Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008;135:620–6, 6 e1–3.
21.
Okada M, Mimura T, Ohbayashi C, Sakuma T, Soejima T, Tsubota N. Radical surgery for malignant pleural mesothelioma: results and prognosis. Interact Cardiovasc Thorac Surg. 2008;7:102–6.PubMedCrossRef
22.
Luckraz H, Rahman M, Patel N, Szafranek A, Gibbs AR, Butchart EG. Three decades of experience in the surgical multi-modality management of pleural mesothelioma. Eur J Cardiothorac Surg. 2010;37:552–6.PubMedCrossRef
23.
Lang-Lazdunski L, Bille A, Lal R, et al. Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma. J Thorac Oncol. 2012;7:737–43.PubMedCrossRef
24.
Cao C, Tian D, Park J, Allan J, Pataky KA, Yan TD. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer. 2014;83:240–45.PubMedCrossRef
25.
Bolukbas S, Eberlein M, Schirren J. Prospective study on functional results after lung-sparing radical pleurectomy in the management of malignant pleural mesothelioma. J Thorac Oncol. 2012;7:900–5.PubMedCrossRef
26.
Rice D, Rusch VW, Pass H, et al. Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma. A Consensus Report of the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group. J Thorac Oncol. 2011;6:1304–12.PubMedCrossRef
27.
Ettinger DS, Akerley W, Borghaei H, et al. Malignant pleural mesothelioma. Clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2012;10:26–41.
28.
Lang-Lazdunski L, Bille A, Belcher E, et al. Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine followed by adjuvant chemotherapy in patients with malignant pleural mesothelioma. J Thorac Oncol. 2011;6:1746–52.PubMedCrossRef
29.
Shimokawa M, Hasegawa S, Fukuoka K, et al. A feasibility study of induction pemetrexed plus cisplatin followed by pleurectomy/decortication aimed at macroscopic complete resection for malignant pleural mesothelioma. Jpn J Clin Oncol. 2013;43:575–8.PubMedCrossRef
30.
Scherpereel A, Astoul P, Baas P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2010;35:479–95.PubMedCrossRef
31.
Committee BTSSoC. BTS statement on malignant mesothelioma in the UK, 2007. Thorax. 2007;62(Suppl 2):ii1–19.
32.
Pinto C, Novello S, Torri V, et al. Second Italian consensus conference on malignant pleural mesothelioma: state of the art and recommendations. Cancer Treat Rev. 2013;39:328–39.PubMedCrossRef
33.
Rusch VW. Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 1997;9:367–72.PubMed
34.
Lee TT, Everett DL, Shu HK, et al. Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2002;124:1183–9.PubMedCrossRef
35.
Bolukbas S, Manegold C, Eberlein M, Bergmann T, Fisseler-Eckhoff A, Schirren J. Survival after trimodality therapy for malignant pleural mesothelioma: radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy. Lung Cancer. 2011;71:75–81.PubMedCrossRef
36.
Friedberg JS, Mick R, Culligan M, et al. Photodynamic therapy and the evolution of a lung-sparing surgical treatment for mesothelioma. Ann Thorac Surg. 2011;91:1738–45.PubMedCrossRef
37.
Nakas A, Trousse DS, Martin-Ucar AE, Waller DA. Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy. Eur J Cardiothorac Surg. 2008;34:886–91.PubMedCrossRef
38.
Weder W, Stahel RA, Bernhard J, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol. 2007;18:1196–202.PubMedCrossRef
39.
Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27:3007–13.PubMedCentralPubMedCrossRef
40.
Van Schil PE, Baas P, Gaafar R, et al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J. 2010;36:1362–9.PubMedCrossRef
41.
Yamanaka T, Tanaka F, Hasegawa S, et al. A feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation for malignant pleural mesothelioma. Jpn J Clin Oncol. 2009;39:186–8.PubMedCrossRef
42.
Federico R, Adolfo F, Giuseppe M, et al. Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma. BMC Cancer. 2013;13:22.PubMedCentralPubMedCrossRef
43.
Rusch V, Saltz L, Venkatraman E, et al. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol. 1994;12:1156–63.PubMed
44.
Richards WG, Zellos L, Bueno R, et al. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol. 2006;24:1561–7.PubMedCrossRef
45.
Rosenzweig KE, Zauderer MG, Laser B, et al. Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2012;83:1278–83.PubMedCrossRef
46.
Rusch VW. Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma. Chest. 1993;103:382S–4S.PubMedCrossRef
47.
Gupta V, Mychalczak B, Krug L, et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2005;63:1045–52.PubMedCrossRef
48.
Minatel E, Trovo M, Polesel J, et al. Radical pleurectomy/decortication followed by high dose of radiation therapy for malignant pleural mesothelioma. Final results with long-term follow-up. Lung Cancer. 2014;83:78–82.PubMedCrossRef
49.
Abraham JW, Zauderer MG, Gomez D, et al. Safety of hemithoracic pleural intensity-modulated radiationtherapy (IMRT) for malignant pleural mesothelioma (MPM) in the multimodality setting: interim analysis of a phase II study. J Thorac Oncol. 2013;8:S346.CrossRef
50.
Pass HI, Temeck BK, Kranda K, Steinberg SM, Feuerstein IR. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 1998;115:310–7 (discussion 7–8).
51.
Sugarbaker DJ, Wolf AS, Chirieac LR, et al. Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy. Eur J Cardiothorac Surg. 2011;40:298–303.PubMed
52.
Sugarbaker DJ, Wolf AS. Surgery for malignant pleural mesothelioma. Expert Rev Respir Med. 2010;4:363–72.PubMedCrossRef
53.
Friedberg JS, Culligan MJ, Mick R, et al. Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2012;93:1658–67.PubMedCrossRef
54.
Bolukbas S, Eberlein M, Kudelin N, et al. Factors predicting poor survival after lung-sparing radical pleurectomy of IMIG stage III malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2013;44:119–23.PubMedCrossRef
Metadata
Title
Extrapleural pneumonectomy or pleurectomy/decortication for malignant pleural mesothelioma
Author
Seiki Hasegawa
Publication date
01-09-2014
Publisher
Springer Japan
Published in
General Thoracic and Cardiovascular Surgery / Issue 9/2014
Print ISSN: 1863-6705
Electronic ISSN: 1863-6713
DOI
https://doi.org/10.1007/s11748-014-0389-7

Other articles of this Issue 9/2014

General Thoracic and Cardiovascular Surgery 9/2014 Go to the issue

Original Article

Optimal surgical management for esophagogastric junction carcinoma

Original Article

The calcified ascending aorta in aortic valve replacement: surgical strategies and results

Current Topics Review Article

Surgical management of locally advanced lung cancer

Current Topics Review Article

Benefits of submitral procedures for ischemic mitral regurgitation

Original Article

Focusing on delayed clearance for identifying small-sized metastatic lung tumors using synchrotron radiation angiography with a highly sensitive receiver

Current Topics Review Article

Perioperative therapy for esophageal cancer